Canada Markets closed

Sanofi (SNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
49.05+0.99 (+2.06%)
At close: 4:00PM EDT
49.50 +0.45 (+0.92%)
After hours: 07:26PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close48.06
Open49.20
Bid48.67 x 1000
Ask49.88 x 800
Day's Range48.94 - 49.52
52 Week Range44.76 - 54.26
Volume3,034,288
Avg. Volume1,973,878
Market Cap122.698B
Beta (5Y Monthly)0.40
PE Ratio (TTM)8.49
EPS (TTM)5.78
Earnings DateN/A
Forward Dividend & Yield1.93 (3.70%)
Ex-Dividend DateMay 03, 2021
1y Target Est63.40
  • Editor's Pick
    Yahoo Finance Video

    Doctor on Covid-19: ‘This is a virus that is really here to stay’

    Dr. Elizabeth Clayborne, Adjunct Assistant Professor of Emergency Medicine at the University of Maryland School of Medicine and Emergency Physician at UM Capital Region Medical Center, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.

  • GlobeNewswire

    FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma

    FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option Only biologic medicine approved for children with oral corticosteroid-dependent asthmaData reinforce well-established safety profile of Dupixent PARIS and TARRYTOWN, N.Y. – October 20, 2021 - The U.S. Food and D

  • Reuters

    Cigna's pharmacy benefit unit to prefer cheaper insulin drug from Viatris

    The unit, Express Scripts, said it expects cost savings of $20 million in 2022 by preferring the Semglee injection. Drugmakers such as Eli Lilly, Sanofi and Novo Nordisk have been under pressure to make their insulin products more affordable amid heavy criticism from lawmakers and patients in a country with a diabetes problem.